DSIP 12 mg

DSIP (Delta Sleep-Inducing Peptide) — 12 mg

Purity: ≥98% (HPLC)
Form: lyophilized powder, 3 ml vial
Storage: −20 °C (before opening), +2…+8 °C (after reconstitution, no more than 28 days)
Verification: Janoshik Analytical (Czech Republic) — independent blind testing of every batch
Synonyms: DSIP, DSIP (ДСИП), Delta Sleep-Inducing Peptide, delta sleep peptide

---

Contents

1. What is DSIP?
2. Why DSIP attracts researchers' attention
3. Peptide structure
4. Delta sleep — in simple terms
5. DSIP and the stress axis (HPA)
6. Studies in humans
7. Open questions — an honest view
8. DSIP and Epithalon — why they are often mentioned together
9. Sources

---

1. What is DSIP?

DSIP (Delta Sleep-Inducing Peptide) is a nonapeptide of nine amino acids, first isolated in 1977 by the Swiss group of Schoenenberger and Monnier from the cerebral venous blood of rabbits in a state of induced sleep [1]. The peptide received its name for its ability to increase the proportion of delta-wave activity on the EEG — that is, to stimulate the deepest, restorative phase of sleep.

DSIP has been detected in human blood and cerebrospinal fluid. It is not a synthetic invention — it is a natural molecule that apparently participates in the regulation of sleep and neuroendocrine processes. Since its discovery, DSIP has become a subject of research in the neurobiology of sleep, stress, and circadian rhythms.

For research use only. Not a medicinal product. Not intended for use in humans or animals.

---

2. Why DSIP attracts researchers' attention

DSIP is of interest not only as a "sleep peptide." It is studied along several directions at once:

• Delta sleep. In the original experiments, intravenous administration of DSIP increased the proportion of delta waves on the EEG — the deep phase of sleep in which the main physical recovery takes place [1][2]. At the same time, unlike benzodiazepines, DSIP did not suppress the REM phase of sleep.

• Stress and cortisol. In rodent models, a reduction in the stress-induced rise of corticosterone, a decrease in stress ulcers, and normalization of disrupted circadian cortisol rhythms have been described [3][4]. DSIP apparently modulates the hypothalamic-pituitary-adrenal (HPA) axis.

• Circadian rhythms. Several animal studies describe normalization of disrupted circadian rhythms, including in models of jet lag and shift work [4].

• Multiple targets. DSIP interacts with GABA receptors, the opioid system, and possibly NMDA receptors — which makes it a neuropharmacologically unusual peptide [2][5].

All data are preclinical (animal models) or come from early, small human studies of the 1980s. No large-scale modern clinical studies of DSIP have been conducted.

---

3. Peptide structure

Parameter	Value
Amino acid sequence	Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu
Short formula	WAGGDASGE
Molecular formula	C₃₅H₄₈N₁₀O₁₅
Molecular weight	~848.81 g/mol
CAS number	62568-57-4
Type	Natural nonapeptide
Detected in	Human blood and cerebrospinal fluid
Half-life	~15 minutes (in vitro)

An interesting detail: DSIP does not belong to any of the known peptide families. Its structure is unique — there is no homology with other neuropeptides [5]. This is one of the reasons why its mechanism of action is still being studied.

---

4. Delta sleep — in simple terms

Sleep consists of several stages that cyclically replace one another throughout the night. The deepest stage is slow-wave sleep, or delta sleep (stage N3 in the modern classification). It is precisely in this phase that:

• The body releases the maximum amount of somatotropin (growth hormone)
• Recovery of muscles, bones, and the immune system takes place
• Declarative memory is consolidated
• Cortisol levels decrease

With age, the proportion of delta sleep decreases. If at 25 years old deep sleep may occupy 20–25% of the night, then after 50 it is often less than 5%. A person sleeps but does not recover. It is precisely this process that makes DSIP a subject of interest in the context of age-related neurobiology.

In experiments, DSIP did not "put to sleep" — it increased the proportion of the deep phase within the structure of sleep that had already set in. This fundamentally distinguishes it from sedative drugs, which suppress wakefulness [3].

---

5. DSIP and the stress axis (HPA)

The hypothalamic-pituitary-adrenal (HPA) axis is the body's main stress circuit. When the brain registers a threat, the hypothalamus releases CRH, the pituitary releases ACTH, and the adrenal glands release cortisol. Cortisol mobilizes resources, increases alertness, and suppresses sleep.

Normally, cortisol follows a daily rhythm: high in the morning (waking), low in the evening (falling asleep). Chronic stress "flattens" this rhythm — cortisol remains elevated toward night, and the delta phase of sleep is the first to suffer.

In rodent experiments, it has been described that DSIP:

• Reduced the stress-induced rise of corticosterone [4]
• Decreased the frequency of stress ulcers under immobilization stress
• Normalized disrupted daily hormone rhythms

Researchers suggest that DSIP acts at the level of the hypothalamus, modulating the release of CRH (corticotropin-releasing hormone) [4]. If this is confirmed, DSIP may prove to be of interest as a molecule acting simultaneously on both sides of the "stress → sleep disruption → stress" cycle.

---

6. Studies in humans

DSIP is one of the few research peptides for which early clinical data exist (albeit limited).

In a series of studies from 1981–1983, Schneider-Helmert and Schoenenberger studied the intravenous administration of DSIP in patients with sleep disorders [3][6]:

• An improvement in subjective sleep quality was described
• A reduction in the time to fall asleep (sleep latency)
• A change in sleep architecture — an increase in the proportion of the slow-wave phase
• The authors noted "improved tolerance of mental stress" and subjective relaxation

These studies were small by modern standards and do not meet the criteria of large randomized controlled trials. Nevertheless, they remain the most direct data on the effect of DSIP on human sleep.

---

7. Open questions — an honest view

Unlike many peptides in the catalog, around DSIP there are unresolved scientific questions that are important to know about:

The DSIP gene has not been found. Despite the fact that the peptide has been detected in human blood and cerebrospinal fluid, the gene encoding DSIP has not been identified. Nor has a specific receptor been found [5]. This is an unusual situation for a biologically active peptide.

Reproducibility results. Some studies on the effect of DSIP on sleep have yielded contradictory results. The review by Graf and Kastin (1984) notes that the connection of DSIP with sleep is "established but not fully characterized" [2].

Short half-life. In vitro, the half-life of DSIP is only ~15 minutes. How a peptide with such instability produces effects lasting hours is a question to which there is as yet no unambiguous answer [5].

These open questions do not negate the observed effects — but they show that DSIP remains an active area of research, not a "solved problem."

---

8. DSIP and Epithalon — why they are often mentioned together

Both peptides are studied in the context of sleep and neuroendocrine regulation, but through different mechanisms:

Parameter	DSIP	Epithalon
Target	Sleep architecture (delta phase), HPA axis	Melatonin (pineal gland), telomerase
Mechanism	Modulation of GABA, the opioid system, cortisol	Activation of AANAT → melatonin synthesis
Focus	Sleep depth, stress resilience	Daily rhythm, cellular aging
Complementarity	Works "inside" sleep architecture	Works with the "clock" — the melatonin cycle

The logic of the combination: Epithalon restores the daily rhythm of melatonin (when to fall asleep and wake up), while DSIP deepens sleep quality within that rhythm (how restorative the sleep will be). In the LONGIVIYA catalog, both peptides are included in Box 02 "Slimness + Longevity."

---

Sources

1. Monnier M., Dudler L., Gächter R., Maier P.F., Schoenenberger G.A., Tissot R. The delta sleep-inducing peptide (DSIP): comparative properties of the original and synthetic nonapeptide. Experientia, 33(4): 548–552, 1977. PubMed

2. Graf M.V., Kastin A.J. Delta-sleep-inducing peptide (DSIP): a review. Neurosci. Biobehav. Rev., 8(1): 83–93, 1984. PubMed

3. Schneider-Helmert D., Gnirss F., Monnier M., Schenker J., Schoenenberger G.A. Acute and delayed effects of DSIP on human sleep behavior. Int. J. Clin. Pharmacol. Ther. Toxicol., 19(8): 341–345, 1981. PubMed

4. Schoenenberger G.A. Characterization, properties and multivariate functions of delta-sleep-inducing peptide (DSIP). Eur. Neurol., 23(5): 321–345, 1984. PubMed

5. Pollard B.J., Pomfrett C.J.D. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. J. Clin. Neurosci., 8(Suppl 1): 1–3, 2001. PubMed

6. Schneider-Helmert D., Schoenenberger G.A. Effects of DSIP in man: multifunctional psychophysiological properties. Neuropsychobiology, 9(2-3): 197–206, 1983.

---

This material was prepared by the LONGIVIYA editorial team based on published scientific research. The information is solely educational in nature and is not a medical recommendation.

For research use only. Not a medicinal product. Not intended for use in humans or animals. Independent verification of every batch: Janoshik Analytical (Czech Republic).